Retractable Technologies, Inc. — FY2017 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2017; it is not a quarterly filing. Retractable Technologies manufactures and markets safety syringes and other medical products. VanishPoint syringes accounted for 89.9% of 2017 revenue, while EasyPoint needles contributed 6.0%. The company reports as one operating segment.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net sales | $34.49 million | $29.83 million |
| Gross profit / margin | $9.97 million / 28.9% | $10.34 million / 34.7% |
| Operating expenses | $13.75 million | $13.85 million |
| Operating loss | $3.78 million | $3.51 million |
| Net loss | $3.74 million | $3.69 million |
| Loss per diluted share | $0.14 | $0.15 |
| Cash used in operating activities | $2.92 million | $0.79 million |
- Sales increased 15.7%; total unit sales rose 28.3%. Domestic revenue increased 2.7%, while international revenue rose from approximately $3.5 million to $7.5 million. International sales represented 21.7% of FY2017 revenue, versus 11.8% in FY2016.
- Gross margin fell 5.8 percentage points, mainly because international sales carried lower average prices. Operating expenses declined 0.7%, with lower legal and impairment costs offset by higher sales staffing, bonuses, and stock-based compensation.
- At year-end, cash and cash equivalents were $14.88 million, current assets $26.61 million, and current liabilities $7.90 million. Cash decreased $1.32 million during 2017.
- Total debt was $3.49 million, including $0.41 million current and $3.08 million long-term. Debt is secured in part by company property. The contractual-obligations schedule reports $3.85 million of future debt payments, including interest.
- Stockholders’ equity was $27.17 million. Preferred dividend requirements were $705,000 for the year; approximately $11.3 million of preferred dividends were in arrears at year-end. No common dividends have been paid.
- Fourth-quarter sales were $9.51 million versus $7.49 million in Q4 2016; Q4 net loss was $1.13 million versus $1.97 million. Quarterly gross margin was 22.9% versus 30.4%.
Material changes, outlook, and risks
- Management said cash reserves, operations, and debt financing when available are expected to fund ongoing needs, but additional borrowing is uncertain. It did not provide quantified revenue or earnings guidance. Management expects EasyPoint demand may increase, but notes new products may not offset potential VanishPoint syringe sales declines after patent coverage expires in 2020.
- In January 2018, Congress extended the moratorium on the 2.3% medical device excise tax through 2019; the tax is scheduled to resume January 1, 2020.
- The company’s appeal followed an August 2017 judgment dismissing its remaining claims against BD and ordering that it take nothing. A separate BD/MDC patent-infringement action remains stayed. Litigation outcomes and costs remain uncertain.
- Manufacturing is concentrated in China: Chinese manufacturers produced 82.9% of products in 2017, and the primary Chinese manufacturer supplied 90.4% of VanishPoint syringes. Disruption could require replacement suppliers or a domestic production ramp, potentially raising costs.
- Patent protection for VanishPoint syringes is expected to expire in 2020; VanishPoint represented 89.9% of revenue in 2017. Other risks include dominant competitors, restricted market access, regulatory and product-liability exposure, international trade risks, and dependence on third-party suppliers.
- The CEO controls 53.8% of common stock and owns the licensed technology. The company pays him a 5% royalty on gross sales; FY2017 royalty expense was $2.86 million. These related-party arrangements and control concentration may present conflicts for other shareholders.
- Unusual items included $1.01 million of insurance proceeds for 2017 storm damage repairs, with $466,293 remaining at year-end, and a $188,000 tax benefit related to the 2017 Tax Act. The company also issued 3 million shares to the CEO in 2017 for total proceeds of $2.35 million.
- The financial statements received an unqualified audit opinion. Management reported effective disclosure controls and internal control over financial reporting, with no material weaknesses identified; the auditor did not express an opinion on internal control effectiveness.
Important facts for investors to verify
- Whether market access, product mix, or pricing can improve gross margins and reduce recurring operating losses and negative operating cash flow.
- The status and potential impact of the BD appeal and the stayed patent-infringement case; no recovery from the appeal is included in FY2017 results.
- Supply continuity, alternative manufacturing capacity, and the costs of replacing or scaling Chinese production.
- Plans and commercial progress for products that could mitigate VanishPoint patent expiration and sales exposure after 2020.
- The amount and priority of preferred dividend arrears, related obligations, and potential dilution from preferred conversions, options, and future share issuances.
- Receivables and distributor rebate estimates: the allowance for doubtful accounts fell from $1.73 million to $102,000 following a write-off of debit rebates, and estimated contractual allowances included in accounts payable were $4.12 million at year-end.